Delaware |
001-36537 |
83-0480694 |
||||||||||||
(State or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Common stock, $0.00001 par value per share | TRUP | The NASDAQ Stock Market LLC |
(d) | Exhibits | |||||||
Exhibit No. | Description | |||||||
Press release regarding financial results issued by Trupanion, Inc. dated November 2, 2023 | ||||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
TRUPANION, INC. | |||||
By: |
/s/ Fawwad Qureshi | ||||
Name: Fawwad Qureshi |
|||||
Title: Chief Financial Officer |
Trupanion, Inc. Condensed Consolidated Statements of Operations (in thousands, except share data) | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Revenue: | |||||||||||||||||||||||
Subscription business | $ | 182,906 | $ | 152,401 | $ | 521,369 | $ | 438,048 | |||||||||||||||
Other business | 102,947 | 81,359 | 291,379 | 221,122 | |||||||||||||||||||
Total revenue | 285,853 | 233,760 | 812,748 | 659,170 | |||||||||||||||||||
Cost of revenue: | |||||||||||||||||||||||
Subscription business(1) |
157,444 | 128,158 | 455,055 | 365,861 | |||||||||||||||||||
Other business | 93,176 | 75,543 | 266,741 | 204,773 | |||||||||||||||||||
Total cost of revenue(2) |
250,620 | 203,701 | 721,796 | 570,634 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Technology and development(1) |
5,302 | 6,553 | 15,434 | 18,178 | |||||||||||||||||||
General and administrative(1) |
12,664 | 10,314 | 46,817 | 28,907 | |||||||||||||||||||
New pet acquisition expense(1) |
17,772 | 22,434 | 60,183 | 67,043 | |||||||||||||||||||
Depreciation and amortization | 2,990 | 2,600 | 9,445 | 8,024 | |||||||||||||||||||
Total operating expenses | 38,728 | 41,901 | 131,879 | 122,152 | |||||||||||||||||||
Gain (loss) from investment in joint venture | 4 | (57) | (140) | (168) | |||||||||||||||||||
Operating loss | (3,491) | (11,899) | (41,067) | (33,784) | |||||||||||||||||||
Interest expense | 3,053 | 1,408 | 8,380 | 2,680 | |||||||||||||||||||
Other income, net | (2,465) | (889) | (6,445) | (1,568) | |||||||||||||||||||
Loss before income taxes | (4,079) | (12,418) | (43,002) | (34,896) | |||||||||||||||||||
Income tax expense (benefit) | (43) | 496 | (472) | 491 | |||||||||||||||||||
Net loss | $ | (4,036) | $ | (12,914) | $ | (42,530) | $ | (35,387) | |||||||||||||||
Net loss per share: | |||||||||||||||||||||||
Basic and diluted | $ | (0.10) | $ | (0.32) | $ | (1.03) | $ | (0.87) | |||||||||||||||
Weighted average shares of common stock outstanding: | |||||||||||||||||||||||
Basic and diluted | 41,536,575 | 40,799,819 | 41,344,195 | 40,707,677 | |||||||||||||||||||
(1)Includes stock-based compensation expense as follows: |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Cost of revenue | $ | 1,176 | $ | 1,472 | $ | 3,801 | $ | 5,138 | |||||||||||||||
Technology and development | 650 | 1,184 | 1,985 | 3,193 | |||||||||||||||||||
General and administrative | 3,281 | 3,792 | 14,448 | 9,281 | |||||||||||||||||||
New pet acquisition expense | 1,785 | 2,195 | 5,626 | 7,214 | |||||||||||||||||||
Total stock-based compensation expense | $ | 6,892 | $ | 8,643 | $ | 25,860 | $ | 24,826 | |||||||||||||||
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows: | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Veterinary invoice expense | $ | 212,441 | $ | 171,112 | $ | 613,316 | $ | 473,654 | |||||||||||||||
Other cost of revenue | 38,179 | 32,589 | 108,480 | 96,980 | |||||||||||||||||||
Total cost of revenue | $ | 250,620 | $ | 203,701 | $ | 721,796 | $ | 570,634 |
Trupanion, Inc. Condensed Consolidated Balance Sheets (in thousands, except share data) | |||||||||||
September 30, 2023 | December 31, 2022 | ||||||||||
(unaudited) | |||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 150,336 | $ | 65,605 | |||||||
Short-term investments | 115,570 | 156,804 | |||||||||
Accounts and other receivables, net of allowance for doubtful accounts of $690 at September 30, 2023 and $540 at December 31, 2022 | 277,913 | 232,439 | |||||||||
Prepaid expenses and other assets | 17,386 | 14,248 | |||||||||
Total current assets | 561,205 | 469,096 | |||||||||
Restricted cash | 18,245 | 19,032 | |||||||||
Long-term investments | 11,434 | 7,841 | |||||||||
Property, equipment and internal-use software, net | 100,730 | 90,701 | |||||||||
Intangible assets, net | 19,770 | 24,031 | |||||||||
Other long-term assets | 18,645 | 18,943 | |||||||||
Goodwill | 42,005 | 41,983 | |||||||||
Total assets | $ | 772,034 | $ | 671,627 | |||||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 8,967 | $ | 9,471 | |||||||
Accrued liabilities and other current liabilities | 29,422 | 32,616 | |||||||||
Reserve for veterinary invoices | 61,338 | 43,734 | |||||||||
Deferred revenue | 246,511 | 202,692 | |||||||||
Long-term debt - current portion | 1,350 | 1,103 | |||||||||
Total current liabilities | 347,588 | 289,616 | |||||||||
Long-term debt | 127,580 | 68,354 | |||||||||
Deferred tax liabilities | 2,583 | 3,392 | |||||||||
Other liabilities | 4,818 | 4,968 | |||||||||
Total liabilities | 482,569 | 366,330 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 42,655,394 and 41,627,208 issued and outstanding at September 30, 2023; 42,041,344 and 41,013,158 shares issued and outstanding at December 31, 2022 | — | — | |||||||||
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding | — | — | |||||||||
Additional paid-in capital | 527,199 | 499,694 | |||||||||
Accumulated other comprehensive loss | (7,108) | (6,301) | |||||||||
Accumulated deficit | (214,092) | (171,562) | |||||||||
Treasury stock, at cost: 1,028,186 shares at September 30, 2023 and December 31, 2022 | (16,534) | (16,534) | |||||||||
Total stockholders’ equity | 289,465 | 305,297 | |||||||||
Total liabilities and stockholders’ equity | $ | 772,034 | $ | 671,627 |
Trupanion, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Operating activities | |||||||||||||||||||||||
Net loss | $ | (4,036) | $ | (12,914) | $ | (42,530) | $ | (35,387) | |||||||||||||||
Adjustments to reconcile net loss to cash provided by (used in) operating activities: | |||||||||||||||||||||||
Depreciation and amortization | 2,990 | 2,600 | 9,445 | 8,024 | |||||||||||||||||||
Stock-based compensation expense | 6,892 | 8,643 | 25,860 | 24,826 | |||||||||||||||||||
Other, net | (549) | 102 | (1,134) | 28 | |||||||||||||||||||
Changes in operating assets and liabilities: | |||||||||||||||||||||||
Accounts and other receivables | (12,409) | (19,821) | (45,593) | (58,948) | |||||||||||||||||||
Prepaid expenses and other assets | 452 | (1,599) | (2,761) | (4,420) | |||||||||||||||||||
Accounts payable, accrued liabilities, and other liabilities | 2,632 | 45 | (3,832) | 748 | |||||||||||||||||||
Reserve for veterinary invoices | 5,258 | 3,061 | 17,697 | 63 | |||||||||||||||||||
Deferred revenue | 10,168 | 17,584 | 43,979 | 56,047 | |||||||||||||||||||
Net cash provided by (used in) operating activities | 11,398 | (2,299) | 1,131 | (9,019) | |||||||||||||||||||
Investing activities | |||||||||||||||||||||||
Purchases of investment securities | (29,458) | (78,292) | (109,389) | (125,660) | |||||||||||||||||||
Maturities and sales of investment securities | 29,713 | 73,280 | 147,365 | 104,492 | |||||||||||||||||||
Cash paid in business acquisition, net of cash acquired | — | (2,755) | — | (2,755) | |||||||||||||||||||
Purchases of property, equipment, and internal-use software | (4,391) | (4,131) | (14,310) | (11,610) | |||||||||||||||||||
Other | 837 | 71 | 1,420 | (1,431) | |||||||||||||||||||
Net cash provided by (used in) investing activities | (3,299) | (11,827) | 25,086 | (36,964) | |||||||||||||||||||
Financing activities | |||||||||||||||||||||||
Proceeds from debt financing, net of financing fees | 24,972 | (119) | 60,102 | 54,312 | |||||||||||||||||||
Repayment of debt financing | (338) | (150) | (1,380) | (300) | |||||||||||||||||||
Repurchases of common stock | — | (4) | — | (5,755) | |||||||||||||||||||
Proceeds from exercise of stock options | 628 | 413 | 1,281 | 1,584 | |||||||||||||||||||
Shares withheld to satisfy tax withholding | (272) | (850) | (1,296) | (3,780) | |||||||||||||||||||
Other | (150) | — | (150) | — | |||||||||||||||||||
Net cash provided by (used in) financing activities | 24,840 | (710) | 58,557 | 46,061 | |||||||||||||||||||
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | (906) | (1,268) | (830) | (1,964) | |||||||||||||||||||
Net change in cash, cash equivalents, and restricted cash | 32,033 | (16,104) | 83,944 | (1,886) | |||||||||||||||||||
Cash, cash equivalents, and restricted cash at beginning of period | 136,548 | 115,087 | 84,637 | 100,869 | |||||||||||||||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 168,581 | $ | 98,983 | $ | 168,581 | $ | 98,983 |
The following tables set forth our key operating metrics: | |||||||||||||||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total pets enrolled (at period end) | 1,712,177 | 1,439,605 | |||||||||||||||||||||||||||||||||||||||||||||
Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total subscription pets enrolled (at period end) | 969,322 | 808,077 | |||||||||||||||||||||||||||||||||||||||||||||
Monthly average revenue per pet | $ | 64.63 | $ | 64.08 | |||||||||||||||||||||||||||||||||||||||||||
Lifetime value of a pet, including fixed expenses | $ | 428 | $ | 673 | |||||||||||||||||||||||||||||||||||||||||||
Average pet acquisition cost (PAC) | $ | 232 | $ | 291 | |||||||||||||||||||||||||||||||||||||||||||
Average monthly retention | 98.55 | % | 98.71 | % | |||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||
Total Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total pets enrolled (at period end) | 1,712,177 | 1,679,659 | 1,616,865 | 1,537,573 | 1,439,605 | 1,348,145 | 1,267,253 | 1,176,778 | |||||||||||||||||||||||||||||||||||||||
Subscription Business: | |||||||||||||||||||||||||||||||||||||||||||||||
Total subscription pets enrolled (at period end) | 969,322 | 943,958 | 906,369 | 869,862 | 808,077 | 770,318 | 736,691 | 704,333 | |||||||||||||||||||||||||||||||||||||||
Monthly average revenue per pet | $ | 65.82 | $ | 64.41 | $ | 63.58 | $ | 63.11 | $ | 63.80 | $ | 64.26 | $ | 64.21 | $ | 63.89 | |||||||||||||||||||||||||||||||
Lifetime value of a pet, including fixed expenses | $ | 428 | $ | 470 | $ | 541 | $ | 641 | $ | 673 | $ | 713 | $ | 730 | $ | 717 | |||||||||||||||||||||||||||||||
Average pet acquisition cost (PAC) | $ | 212 | $ | 236 | $ | 247 | $ | 283 | $ | 268 | $ | 309 | $ | 301 | $ | 306 | |||||||||||||||||||||||||||||||
Average monthly retention | 98.55 | % | 98.61 | % | 98.65 | % | 98.69 | % | 98.71 | % | 98.74 | % | 98.75 | % | 98.74 | % |
The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands): | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Net cash provided by (used in) operating activities | $ | 11,398 | $ | (2,299) | $ | 1,131 | $ | (9,019) | |||||||||||||||
Purchases of property, equipment, and internal-use software | (4,391) | (4,131) | (14,310) | (11,610) | |||||||||||||||||||
Free cash flow | $ | 7,007 | $ | (6,430) | $ | (13,179) | $ | (20,629) |
The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages): | ||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
Veterinary invoice expense | $ | 212,441 | $ | 171,112 | $ | 613,316 | $ | 473,654 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(870) | (960) | (2,565) | (3,155) | ||||||||||||||||||||||
Other business cost of paying veterinary invoices | (72,694) | (58,197) | (210,286) | (152,911) | ||||||||||||||||||||||
Subscription cost of paying veterinary invoices (non-GAAP) | $ | 138,877 | $ | 111,955 | $ | 400,465 | $ | 317,588 | ||||||||||||||||||
% of subscription revenue | 75.9 | % | 73.5 | % | 76.8 | % | 72.5 | % | ||||||||||||||||||
Other cost of revenue | $ | 38,179 | $ | 32,589 | $ | 108,480 | $ | 96,980 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(282) | (433) | (1,158) | (1,818) | ||||||||||||||||||||||
Other business variable expenses | (20,482) | (17,346) | (56,455) | (51,862) | ||||||||||||||||||||||
Subscription variable expenses (non-GAAP) | $ | 17,415 | $ | 14,810 | $ | 50,867 | $ | 43,300 | ||||||||||||||||||
% of subscription revenue | 9.5 | % | 9.7 | % | 9.8 | % | 9.9 | % | ||||||||||||||||||
Technology and development expense | $ | 5,302 | $ | 6,553 | $ | 15,434 | $ | 18,178 | ||||||||||||||||||
General and administrative expense | 12,664 | 10,314 | 46,817 | 28,907 | ||||||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(3,754) | (4,805) | (16,072) | (12,116) | ||||||||||||||||||||||
Non-recurring transaction or restructuring expenses2 |
(8) | (179) | (4,175) | (179) | ||||||||||||||||||||||
Development expenses3 |
(1,594) | (2,435) | (3,417) | (5,705) | ||||||||||||||||||||||
Fixed expenses (non-GAAP) | $ | 12,610 | $ | 9,448 | $ | 38,587 | $ | 29,085 | ||||||||||||||||||
% of total revenue | 4.4 | % | 4.0 | % | 4.7 | % | 4.4 | % | ||||||||||||||||||
New pet acquisition expense | $ | 17,772 | $ | 22,434 | $ | 60,183 | $ | 67,043 | ||||||||||||||||||
Less: | ||||||||||||||||||||||||||
Stock-based compensation expense1 |
(1,679) | (2,108) | (5,433) | (7,037) | ||||||||||||||||||||||
Other business pet acquisition expense | (10) | (181) | (123) | (476) | ||||||||||||||||||||||
Subscription acquisition cost (non-GAAP) | $ | 16,083 | $ | 20,145 | $ | 54,627 | $ | 59,530 | ||||||||||||||||||
% of subscription revenue | 8.8 | % | 13.2 | % | 10.5 | % | 13.6 | % | ||||||||||||||||||
1Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.3 million and $0.6 million for the three and nine months ended September 30, 2023, respectively. | ||||||||||||||||||||||||||
2Consists of business acquisition transaction expenses, severance and legal costs due to certain executives' departures, and a $3.8 million non-recurring settlement of accounts receivable in the first quarter of 2023 related to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers. | ||||||||||||||||||||||||||
3As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend. |
The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages): | |||||||||||||||||||||||
By Segment: | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Subscription revenue | $ | 182,906 | $ | 152,401 | $ | 521,369 | $ | 438,048 | |||||||||||||||
Subscription cost of paying veterinary invoices | 138,877 | 111,955 | 400,465 | 317,588 | |||||||||||||||||||
Subscription variable expenses | 17,415 | 14,810 | 50,867 | 43,300 | |||||||||||||||||||
Subscription fixed expenses* | 8,069 | 6,160 | 24,753 | 19,354 | |||||||||||||||||||
Subscription adjusted operating income | 18,545 | 19,476 | 45,284 | 57,806 | |||||||||||||||||||
Other business revenue | 102,947 | 81,359 | 291,379 | 221,122 | |||||||||||||||||||
Other business cost of paying veterinary invoices | 72,694 | 58,197 | 210,286 | 152,911 | |||||||||||||||||||
Other business variable expenses | 20,482 | 17,346 | 56,455 | 51,862 | |||||||||||||||||||
Other business fixed expenses* | 4,541 | 3,288 | 13,834 | 9,731 | |||||||||||||||||||
Other business adjusted operating income | 5,230 | 2,528 | 10,804 | 6,618 | |||||||||||||||||||
Subscription acquisition cost | 16,083 | 20,145 | 54,627 | 59,530 | |||||||||||||||||||
Other business acquisition cost | 10 | 181 | 123 | 476 | |||||||||||||||||||
Development expenses | 1,594 | 2,435 | 3,417 | 5,705 | |||||||||||||||||||
Stock-based compensation expense | 6,585 | 8,306 | 25,228 | 24,126 | |||||||||||||||||||
Depreciation and amortization | 2,990 | 2,600 | 9,445 | 8,024 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses |
8 | 179 | 4,175 | 179 | |||||||||||||||||||
Gain (loss) from investment in joint venture | 4 | (57) | (140) | (168) | |||||||||||||||||||
Operating loss | (3,491) | (11,899) | (41,067) | (33,784) | |||||||||||||||||||
As a percentage of revenue: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Subscription revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Subscription cost of paying veterinary invoices | 75.9 | % | 73.5 | % | 76.8 | % | 72.5 | % | |||||||||||||||
Subscription variable expenses | 9.5 | % | 9.7 | % | 9.8 | % | 9.9 | % | |||||||||||||||
Subscription fixed expenses* | 4.4 | % | 4.0 | % | 4.7 | % | 4.4 | % | |||||||||||||||
Subscription adjusted operating income | 10.1 | % | 12.8 | % | 8.7 | % | 13.2 | % | |||||||||||||||
Other business revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Other business cost of paying veterinary invoices | 70.6 | % | 71.5 | % | 72.2 | % | 69.2 | % | |||||||||||||||
Other business variable expenses | 19.9 | % | 21.3 | % | 19.4 | % | 23.5 | % | |||||||||||||||
Other business fixed expenses* | 4.4 | % | 4.0 | % | 4.7 | % | 4.4 | % | |||||||||||||||
Other business adjusted operating income | 5.1 | % | 3.1 | % | 3.7 | % | 3.0 | % |
Total Business: | |||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Revenue | $ | 285,853 | $ | 233,760 | $ | 812,748 | $ | 659,170 | |||||||||||||||
Cost of paying veterinary invoices | 211,571 | 170,152 | 610,751 | 470,499 | |||||||||||||||||||
Variable expenses | 37,897 | 32,156 | 107,322 | 95,162 | |||||||||||||||||||
Fixed expenses | 12,610 | 9,448 | 38,587 | 29,085 | |||||||||||||||||||
Adjusted operating income | 23,775 | 22,004 | 56,088 | 64,424 | |||||||||||||||||||
Acquisition cost | 16,093 | 20,326 | 54,750 | 60,006 | |||||||||||||||||||
Development expenses | 1,594 | 2,435 | 3,417 | 5,705 | |||||||||||||||||||
Stock-based compensation expense | 6,585 | 8,306 | 25,228 | 24,126 | |||||||||||||||||||
Depreciation and amortization | 2,990 | 2,600 | 9,445 | 8,024 | |||||||||||||||||||
Non-recurring transaction or restructuring expenses |
8 | 179 | 4,175 | 179 | |||||||||||||||||||
Gain (loss) from investment in joint venture | 4 | (57) | (140) | (168) | |||||||||||||||||||
Operating loss | (3,491) | (11,899) | (41,067) | (33,784) | |||||||||||||||||||
As a percentage of revenue: | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||||||
Cost of paying veterinary invoices | 74.0 | % | 72.8 | % | 75.1 | % | 71.4 | % | |||||||||||||||
Variable expenses | 13.3 | % | 13.8 | % | 13.2 | % | 14.4 | % | |||||||||||||||
Fixed expenses | 4.4 | % | 4.0 | % | 4.7 | % | 4.4 | % | |||||||||||||||
Adjusted operating income | 8.3 | % | 9.4 | % | 6.9 | % | 9.8 | % | |||||||||||||||
Acquisition cost | 5.6 | % | 8.7 | % | 6.7 | % | 9.1 | % | |||||||||||||||
Development expenses | 0.6 | % | 1.0 | % | 0.4 | % | 0.9 | % | |||||||||||||||
Stock-based compensation expense | 2.3 | % | 3.6 | % | 3.1 | % | 3.7 | % | |||||||||||||||
Depreciation and amortization | 1.0 | % | 1.1 | % | 1.2 | % | 1.2 | % | |||||||||||||||
Non-recurring transaction or restructuring expenses |
— | % | 0.1 | % | 0.5 | % | — | % | |||||||||||||||
Gain (loss) from investment in joint venture | — | % | — | % | — | % | — | % | |||||||||||||||
Operating loss | (1.2) | % | (5.1) | % | (5.1) | % | (5.1) | % |
The following tables reflect the reconciliation of adjusted EBITDA to net loss (in thousands): | |||||||||||||||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ | (42,530) | $ | (35,387) | |||||||||||||||||||||||||||||||||||||||||||
Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 25,228 | 24,125 | |||||||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense | 9,445 | 8,024 | |||||||||||||||||||||||||||||||||||||||||||||
Interest income | (6,169) | (1,412) | |||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 8,380 | 2,680 | |||||||||||||||||||||||||||||||||||||||||||||
Other non-operating expenses | — | (1) | |||||||||||||||||||||||||||||||||||||||||||||
Income tax (benefit) expense | (472) | 491 | |||||||||||||||||||||||||||||||||||||||||||||
Non-recurring transaction or restructuring expenses | 4,175 | 179 | |||||||||||||||||||||||||||||||||||||||||||||
(Gain) loss from equity method investment | (110) | (131) | |||||||||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | (2,053) | $ | (1,432) | |||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||
Net loss | $ | (4,036) | $ | (13,714) | $ | (24,780) | $ | (9,285) | $ | (12,914) | $ | (13,618) | $ | (8,855) | $ | (7,042) | |||||||||||||||||||||||||||||||
Excluding: | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 6,585 | 6,503 | 12,140 | 8,412 | 8,306 | 8,462 | 7,358 | 6,808 | |||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense | 2,990 | 3,253 | 3,202 | 2,897 | 2,600 | 2,707 | 2,717 | 2,770 | |||||||||||||||||||||||||||||||||||||||
Interest income | (2,389) | (2,051) | (1,729) | (1,614) | (1,018) | (297) | (97) | (80) | |||||||||||||||||||||||||||||||||||||||
Interest expense | 3,053 | 2,940 | 2,387 | 1,587 | 1,408 | 1,193 | 79 | 9 | |||||||||||||||||||||||||||||||||||||||
Other non-operating expenses | — | — | — | — | — | (1) | — | — | |||||||||||||||||||||||||||||||||||||||
Income tax expense (benefit) | (43) | (238) | (191) | (15) | 496 | 19 | (24) | 1,034 | |||||||||||||||||||||||||||||||||||||||
Non-recurring transaction or restructuring expenses | 8 | 65 | 4,102 | 193 | 179 | — | — | — | |||||||||||||||||||||||||||||||||||||||
(Gain) loss from equity method investment | (110) | — | — | — | — | (131) | — | — | |||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 6,058 | $ | (3,242) | $ | (4,869) | $ | 2,175 | $ | (943) | $ | (1,666) | $ | 1,178 | $ | 3,499 | |||||||||||||||||||||||||||||||